VHL and renal cell carcinoma: Recently, belzutifan was approved by the Food and Drug Administration (FDA) for adult patients with VHL-associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors without the need for immediate surgery [68].